Gaucher disease, the most prevalent lysosomal storage disease, is characterised by a significant phenotypic variation caused by more than 150 mutations. In order to verify pathogenicity of mutations found in the Czech Gaucher population, the vaccinia expression system was used. The wild-type human bglucocerebrosidase cDNA and cDNAs carrying the mutations 72delC, 1326insT, 1263del55, S196P, N370S, L444P, G202E, D409H, T369M, L444P+V460V, and D409H+T369M were expressed in Gaucher fibroblast cell line (L444P/S107L), BSC40, and HeLa G cells. The enzymatic activity and immunological reactivity were analysed. Only b-glucocerebrosidase-deficient fibroblasts were suitable for expression using plasmid transfection. The expressed b-glucosidase activity of mutant glucocerebrosidases was in good correlation with the presumed severity of the mutations.
Introduction
Gaucher disease is a sphingolipid storage disorder caused by a hereditary deficiency of lysosomal hydrolase bglucocerebrosidase. Glucocerebrosidase cleaves the bglycosidic bond between the ceramide and glucose moieties of glucosylceramide and its deficiency leads to storage of glucosylceramide, preferentially in the cells of monocyte -macrophage origin. Patients usually present with splenomegaly, hepatomegaly, thrombocytopenia, and often with bone disease. Three clinical types of the disease are recognised on the basis of the progression of the disease and CNS involvement: type 1 (non-neuronopathic), type 2 (acute neuronopathic) and type 3 (subacute neuronopathic). Clinical manifestation in the most prevalent type 1 is heterogeneous. 1 More than 150 glucocerebrosidase gene mutations were described in Gaucher patients (http://archive.uwcm.ac.uk/ uwcm/mg/search/119262.html). In non-Jewish populations common mutations account for about 70% of mutant alleles, the rest of the alleles are occupied by rare or private mutations. From the prevalent mutations only three cell lines were derived from homozygous patients (N370S, L444P, and D409H), thus enabling the study of the properties of the appropriate mutant protein. Therefore, in vitro expression of mutant protein is necessary for the study of other mutant glucocerebrosidases. Most importantly, in vitro expression of the mutant protein and its activity is necessary to distinguish between missense mutation and a neutral polymorphism.
Since glucocerebrosidase is a glycoprotein and glycosylation is necessary for its catalytic activity, expression in eukaryotic systems is necessary for the functional studies of mutant glucocerebrosidase. Glucocerebrosidase has been previously expressed in COS cells, however, the activity of the expressed wild-type glucocerebrosidase was only two or three times higher than the endogenous b-glucosidase activity of the cell line. 2 Higher levels of expression were achieved in virus-based systems. Expression of glucocerebrosidase in baculovirus enabled very high levels of expression and to some extent allowed to tell the differences between mutant proteins. 2 -4 Vaccinia virus-driven expression allowed very high levels of expression of the recombinant proteins. Measurements of enzymatic activity in cells loaded with fluorophorlabelled glucosylceramide showed that the degree of residual activity of the mutant glucocerebrosidases correlated well with phenotypes associated with individual mutations. 5 For routine evaluation of mutant alleles an expression using plasmid transfection, which does not require timeconsuming selection and purification of mutant viruses, may prove useful. The aim of this work was to test the capability of plasmid transfection-based expression of glucocerebrosidase to differentiate between deleterious and neutral mutations.
Materials and methods
Plasmid construction pTM1-glu1 containing wild-type glucocerebrosidase cDNA under control T7 promotor was used as the expression vector. The vector contained both glucocerebrosidase ATG codons. It was shown to achieve higher levels of enzyme expression than vectors containing only one of the ATG codons. 6 Transformert Site-Directed Mutagenesis Kit (Clontech Laboratories, Inc.) was used, according to the manufacturer's recommendations for the introduction of mutations listed in Table 2 , into the vector. The sequences were confirmed by sequencing.
Cells
HeLa G cells and BSC40 cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) neonatal calf serum (NCS) (Gibco).
Gaucher fibroblasts (L444P/S107L) were grown in DMEM containing 10% fetal calf serum (FCS). This primary fibroblast cell line was obtained from type 2 Gaucher patient (patient number #24, Hodanova et al 7 ) .
Thymidine kinase-deficient 143 cells (143 TK(À)) were grown in DMEM supplemented with 10% FCS and 25 ml/ml 5-bromodeoxyuridine. All cells were grown at 371C in the presence of 5% CO 2 and 95% humidity.
Viruses
Wild-type vaccinia virus strain (WR), recombinant vaccinia virus expressing the T7 RNA polymerase (vTF7-3), and recombinant viruses (harbouring normal or mutated glucocerebrosidase cDNAs: v-WT-glu1, v-72delC, v1326insT, and v-S196P) were used.
Recombinant viruses were generated, selected with bromodeoxyuridine, and purified according to standard protocols. 8 Briefly, four recombinant vaccinia viruses expressing wild-type and mutated glucocerebrosidase cDNAs under the control of T7 promoter were prepared. Three to five rounds of selection were required to purify the viruses to homogeneity, which was verified by Southern blotting. The sequence of the glucocerebrosidase minigenes was verified by direct sequencing of the viral DNA or sequencing of PCR products where vaccinia genomic DNA served as the template, to exclude the possibility that mutations were introduced into the inserts during selection with bromodeoxyuridine. Plasmid transfection BSC40 or fibroblast cells (0.2 Â 10 6 ) were infected with vTF7-3 vaccinia virus (10 PFU/cell) in a serum-free medium. After 1 h, the virus was removed and the cells were transfected with 1.5 mg plasmid DNA using 5 ml LipofectACE (Gibco). After 4 h, serum (FCS) was added to the final concentration 2%. After 24 h, cell lysates were prepared and samples were assayed.
Infection
Enzymatic activity b-glucosidase activity was measured spectrofluorometrically with 4-methylumbelliferyl b-D-glucopyranoside as a substrate. 9 Protein concentration was estimated using the 2-bicinchoninic acid protein assay (Pierce Chemical, Antwerp, Belgium).
Western blotting
Cell lysates containing 10 mg of protein were subjected to SDS-PAGE and Western blotting and immunodetection were performed as previously described.
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Polyclonal anti-glucocerebrosidase antibody 0126 (a kind gift of Dr Aerts) was used as the primary antibody.
Patients
Mutations found in a cohort of Czech and Slovak patients were selected for expression studies. The clinical and Expression of glucocerebrosidase in vaccinia K Hodaňová et al laboratory features of the patients are summarised in Table 1 and by Hodanova et al. 7 The numbering of patients is identical to the previous study. 7 The previously described mutant allele 72delC, which produces a shift of reading frame and a stop 51 amino acids downstream the normal protein cleavage site, was also included. 11 The previously characterised common mutations, N370S and L444P 5 , were re-expressed for comparison.
Results
Site-directed mutagenesis Expression vectors carrying mutations: 72delC, 1326insT, 1263del55, S196P, N370S, L444P, G202E, D409H, T369M, L444P+V460V and D409H+T369M were prepared by sitedirected mutagenesis. The inserted part of the vector was sequenced to verify that only the desired mutation was present in the cDNA minigene.
Expression of wild-type and mutant glucocerebrosidases Expression of glucocerebrosidase by recombinant vaccinia viruses yielded very high levels of b-glucosidase activity.
The average expressed activity of wild-type glucocerebrosidase in BSC40 cell line was 1200 (7600) nmol/mg/h. The average endogenous b-glucosidase activity of these cells constituted about 3% of the above activity. All mutant glucocerebrosidase forms had activity lower than 5% of the expressed wild-type. The activity of glucocerebrosidase carrying the missense mutation S196P was more than twice higher than that presented by other tested mutations (See Table 2 ). The L444P/S107L fibroblast cell line had no measurable endogenous b-glucosidase activity (o1% of b-glucosidase activity of control fibroblasts).
We have also attempted to use HeLa G cells, but the endogenous activity of the cells infected with vTF7-3 virus accounted for more than 70% of total b-glucosidase activity of expressed wild-type human glucocerebrosidase (data not shown).
In all, 11 mutant and wild-type glucocerebrosidase forms were expressed from plasmids in the Gaucher fibroblast cell line. The expressed glucocerebrosidase proteins carried missense mutations (S196P, N370S, L444P, G202E, D409H, T369M), null mutations -insertion, deletions (72delC, 1326insT, 1263del55), and complex mutations (L444P+V460V, D409H+T369M). The mutations S196P, G202E, 1326insT, and complex mutations (L444P+V460V, Plasmid expression of wild-type glucocerebrosidase yielded significantly lower levels (less than 16%) of expression compared to that achieved by expression driven by recombinant virus. The average activity of wild-type glucocerebrosidase was 105 (760) nmol/mg/h in BSC40 and 207(790) nmol/mg/h in fibroblasts. The activities of mutant glucocerebrosidases were 10% of the normal activity, with the exception of T369M, whose activity reached 40% of wild-type glucocerebrosidase. Activity of all mutant glucocerebrosidase forms was significantly reduced, although it was not possible to distinguish reliably the severity of mutations.
The amount of protein directed by the different mutated alleles was tested by Western blotting. The expressed wildtype human b-glucocerebrosidase strongly reacted with the polyclonal anti-human b-glucocerebrosidase antibody and produced a multiple-band pattern that corresponds to differentially glycosylated forms of the enzyme. The same pattern was observed for mutant glucocerebrosidase forms (see Figures 1a and b) .
When expressed from recombinant virus no immunoreactive protein was detected in the null mutation 72delC, while the amount of immunoreactive protein in mutation S196P was comparable to that of wild-type glucocebrosidase. A reduced amount of immunoreactive protein with a molecular weight lower than that of the wild-type glucocerebrosidase was detected in mutation 1326insT.
A reduced amount of immunoreactive protein was detected in cells transfected with plasmids carrying the missense mutations: G202E, D409H, T369M, N370S, S196P, and D409H+T369M. No protein was detected in the alleles carrying the mutations: L444P, complex (L444P+V460V), and several null mutations (72delC, 1326insT, and 1236del55).
Discussion
Glycosylation is necessary for catalytic activity of glucocerebrosidase. The expression in eukaryotic expression systems is thus mandatory for the functional studies of mutant glucocerebrosidase. Baculovirus-based system was used for the expression of mutant glucocerebrosidases and to some extent allowed to differentiate between activities of individual mutant enzymes. The endogenous activity of the cell line used for expression may present a serious obstacle in the evaluation of the low residual activity of mutant glucocerebrosidase forms. We used three cell lines (HeLa G, BSC40, and Gaucher fibroblasts L444P/S107L). The endogenous b-glucosidase activity of the HeLa G cell line was very high (70%), therefore it could not be used for transient expression.
The endogenous activity of BSC40 cells constituted about 25% of the total b-glucosidase activity of the transiently expressed wild-type glucocerebrosidase and therefore the cells were efficient for infection experiments. Gaucher fibroblasts L444P/S107L had no detectable b-glucosidase activity (less than 0.1% of controls) and were suitable even for expression using plasmids.
The pathogenicity of five novel mutations found in Czech Gaucher patients has been verified and the deleterious effect on catalytic activity of six known mutations was confirmed.
The glucocerebrosidase forms carrying null mutations (72delC, 1326insT, and 1263del55) had lower b-glucosidase activity (average activity was less than 2% of wild-type glucocerebrosidase activity) than the missense mutations (S196P, N370S, L444P, G202E, and D409H) where average activity was 3 -10% of that of the wild-type.
Residual activity significantly higher than that presented by the mild N370S mutation was observed for the T369M (9.3 and 40.4 % of wild-type glucocerebrosidase activity, respectively). This may suggest that the T369M is a very mild mutation, even on the verge of polymorphism. This statement is also supported by the mild phenotype of two siblings who are compound heterozygotes for mutations N370S and T369M. 12 However, the activity of the mutant protein with the natural substrate was not studied. The S196P produced high steady-state levels of mutant protein with severely reduced enzyme activity. According to classification proposed by Beutler and Gelbart, 14 the S196P is apparently a severe mutation, as it was found in homozygosity in a type 2 patient. 15 This corresponds well with the moderate to severe phenotype observed in patient 11, who carries mutations N370S and S196P. Undetectable amount of immunoreactive protein was found in frameshifts and also in missense mutation L444P when expressed from plasmid. The L444P is known to produce active, but unstable protein. 16 Notable steadystate amounts of L444P mutant protein were found by Pasmanik-Chor et al. 5 using vaccinia virus expression system, which produces significantly higher amounts of recombinant protein. The amount of the unstable L444P glucocerebrosidase expressed using plasmid transfection may be below the detection limit of Western blotting. Indeed, when glucocerebrosidase with frameshift 1326insT was expressed from recombinant vaccinia virus, a low amount of immunoreactive glucocerebrosidase with lower molecular weight was detected by Western blotting. No immunoreactive material, however, was detected when the same mutant protein was expressed from plasmid. In plasmid transfection the level of expression depends largely on the efficiency of the transfection, which may vary in each experiment. In spite of that the pathogenic mutations could be clearly distinguished from polymorphisms. Transient vaccinia virus-driven expression of glucocerebrosidase in deficient human cell lines thus enables reliable differentiation of deleterious and neutral mutations.
While the expression of mutant glucocerebrosidase determines a residual activity of the enzyme and possibly also the severity of the mutation, the prediction of the phenotype on the basis of genotype remains imprecise. This suggests that there are other genetic and enviromental factors which modulate the phenotype of Gaucher patients. Also, owing to presumably dimeric structure of native glucocerebrosidase 17 , it cannot be excluded that different mutant glucocerebrosidases influence each other in compound heterozygotes.
